List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7207759/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
2	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and αâ€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
3	Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiology of Disease, 2020, 137, 104782.	4.4	241
4	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
5	Genetic risk factors in Parkinson's disease. Cell and Tissue Research, 2018, 373, 9-20.	2.9	159
6	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
7	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
8	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. American Journal of Human Genetics, 2015, 96, 938-947.	6.2	109
9	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Movement Disorders, 2021, 36, 1420-1429.	3.9	108
10	The role of monogenic genes in idiopathic Parkinson's disease. Neurobiology of Disease, 2019, 124, 230-239.	4.4	97
11	Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	5.3	95
12	The Parkinson's Disease <scp>Genomeâ€Wide</scp> Association Study Locus Browser. Movement Disorders, 2020, 35, 2056-2067.	3.9	68
13	Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathologica, 2020, 140, 341-358.	7.7	68
14	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
15	Parkinson's disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
16	Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Science Advances, 2021, 7, .	10.3	59
17	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
18	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	3.9	50

#	Article	lF	CITATIONS
19	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
20	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
21	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. Annals of Neurology, 2021, 89, 803-812.	5.3	38
22	Proteotoxicity and Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 5646.	4.1	37
23	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. Neurobiology of Aging, 2016, 45, 213.e3-213.e9.	3.1	35
24	Heritability Enrichment Implicates Microglia in Parkinson's Disease Pathogenesis. Annals of Neurology, 2021, 89, 942-951.	5.3	35
25	Comprehensive assessment of PINK1 variants in Parkinson's disease. Neurobiology of Aging, 2020, 91, 168.e1-168.e5.	3.1	32
26	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
27	The <i>CACNA1B</i> R1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort. Human Molecular Genetics, 2015, 24, 5326-5329.	2.9	28
28	Heterozygous <i>PRKN</i> mutations are common but do not increase the risk of Parkinson's disease. Brain, 2022, 145, 2077-2091.	7.6	26
29	Analysis of the genetic variability in Parkinson's disease from Southern Spain. Neurobiology of Aging, 2016, 37, 210.e1-210.e5.	3.1	23
30	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
31	Mendelian Randomization—A Journey From Obscurity to Center Stage With a Few Potholes Along the Way. JAMA Neurology, 2020, 77, 7.	9.0	21
32	An Examination of the Mechanisms Involved in Secondary Clinical Failure to Adalimumab or Etanercept in Inflammatory Arthropathies. Journal of Clinical Rheumatology, 2015, 21, 115-119.	0.9	19
33	ARSA variants in α-synucleinopathies. Brain, 2019, 142, e70-e70.	7.6	17
34	Tumor Necrosis Factor Inhibition and Parkinson Disease. Neurology, 2021, 96, e1672-e1679.	1.1	17
35	Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 792227.	2.4	17
36	Genetic Risk Profiling in Parkinson's Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways. International Journal of Molecular Sciences, 2020, 21, 7332.	4.1	16

#	Article	IF	CITATIONS
37	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
38	Unhealthy Behaviours and Risk of Parkinson's Disease: A Mendelian Randomisation Study. Journal of Parkinson's Disease, 2021, 11, 1981-1993.	2.8	16
39	LRP10 in α-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
40	ATP10B and the risk for Parkinson's disease. Acta Neuropathologica, 2020, 140, 401-402.	7.7	14
41	Genetic Stratification of Ageâ€Dependent Parkinson's Disease Risk by Polygenic Hazard Score. Movement Disorders, 2022, 37, 62-69.	3.9	13
42	Alphaâ€synuclein triggers Tâ€cell response. Is Parkinson's disease an autoimmune disorder?. Movement Disorders, 2017, 32, 1327-1327.	3.9	12
43	Lack of evidence for genetic association of saposins A, B, C and D with Parkinson's disease. Brain, 2020, 143, e72-e72.	7.6	11
44	Evaluating Lipid‣owering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization. Annals of Neurology, 2020, 88, 1043-1047.	5.3	11
45	Exome-wide rare variant analysis in familial essential tremor. Parkinsonism and Related Disorders, 2021, 82, 109-116.	2.2	11
46	The Parkinson's Disease <scp>DNA</scp> Variant Browser. Movement Disorders, 2021, 36, 1250-1258.	3.9	11
47	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. Neurobiology of Aging, 2021, 103, 142.e1-142.e5.	3.1	11
48	Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells, 2021, 10, 1030.	4.1	11
49	<scp>αâ€Synuclein</scp> Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease. Movement Disorders, 2021, 36, 2346-2357.	3.9	11
50	Structural genomic variations and Parkinson's disease. Minerva Medica, 2017, 108, 438-447.	0.9	11
51	Genome-wide estimates of heritability and genetic correlations in essential tremor. Parkinsonism and Related Disorders, 2019, 64, 262-267.	2.2	10
52	No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease. Neurobiology of Aging, 2020, 87, 140.e19-140.e22.	3.1	10
53	Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. Annals of Neurology, 2022, 92, 270-278.	5.3	10
54	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of α-synuclein. Cell Reports, 2021, 35, 109189.	6.4	8

#	Article	IF	CITATIONS
55	Predicting progression in patients with Parkinson's disease. Lancet Neurology, The, 2017, 16, 860-862.	10.2	7
56	Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans. Neurobiology of Aging, 2021, 101, 297.e1-297.e4.	3.1	7
57	Mapping the Diverse and Inclusive Future of Parkinson's Disease Genetics and Its Widespread Impact. Genes, 2021, 12, 1681.	2.4	7
58	Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. Journal of Personalized Medicine, 2021, 11, 169.	2.5	6
59	Immunogenetic Determinants of Parkinson's Disease Etiology. Journal of Parkinson's Disease, 2022, 12, S13-S27.	2.8	6
60	<i>MIDN</i> locus structural variants and Parkinson's Disease risk. Annals of Clinical and Translational Neurology, 2020, 7, 602-603.	3.7	5
61	A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of Disease, 2021, 148, 105182.	4.4	5
62	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	2.8	5
63	Assessment of Genetic Association Between Parkinson Disease and Bipolar Disorder. JAMA Neurology, 2020, 77, 1034.	9.0	4
64	Assessment of LIN28A variants in Parkinson's disease in large European cohorts. Neurobiology of Aging, 2021, 100, 118.e1-118.e3.	3.1	4
65	The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset. Neurobiology of Aging, 2021, 97, 144.e1-144.e3.	3.1	3
66	Replication assessment of NUS1 variants in Parkinson's disease. Neurobiology of Aging, 2021, 101, 300.e1-300.e3.	3.1	3
67	No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 801-809.	2.8	3
68	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. Movement Disorders, 2021, 36, 1967-1972.	3.9	3
69	The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes. International Journal of Molecular Sciences, 2021, 22, 8100.	4.1	3
70	Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics. Movement Disorders, 2022, 37, 1559-1561.	3.9	3
71	The appendix and the risk of Parkinson's disease: Appended notes on correlation and causation. Movement Disorders, 2019, 34, 199-199.	3.9	2
72	Unraveling the genetic complexity of Alzheimer disease with Mendelian Randomization. Neurology: Genetics, 2019, 5, e313.	1.9	1

#	Article	IF	CITATIONS
73	Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease. Neurobiology of Aging, 2021, 107, 178-180.	3.1	1
74	Common and rare variants in HFE are not associated with Parkinson's disease in Europeans. Neurobiology of Aging, 2021, 107, 174-177.	3.1	1
75	Assessment of ANG variants in Parkinson's disease. Neurobiology of Aging, 2021, 104, 111.e1-111.e4.	3.1	1
76	Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication. Movement Disorders, 2021, 36, 2506-2507.	3.9	1
77	RIC3 variants are not associated with Parkinson's disease in large European, Latin American, or East Asian cohorts. Neurobiology of Aging, 2022, 109, 264-268.	3.1	0
78	17q21.31 Sub-Haplotypes Underlying H1-Associated Risk for Parkinson's Disease and Progressive Supranuclear Palsy Converge on Altered Glial Regulation. SSRN Electronic Journal, 0, , .	0.4	0